Clinical trials: Hypersomnia, open to volunteers
Idiopathic Hypersomnia, POTS - Postural Orthostatic Tachycardia Syndrome
Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome
The investigators hope to learn if low sodium oxybate (LXB) is an effective treatment for symptoms of idiopathic hypersomnia (IH) and postural tachycardia syndrome (POTS).
- Trial name
- NCT07077278
- Testing
- Low sodium oxybate (LXB)
- Volunteers
- 25 people
- Sponsor
- Stanford University
Narcolepsy, Social Cognition
Evaluation of Social Cognition in Patient With Type 1 or Type 2 Narcolepsy Versus Patients With Idiopathic Hypersomnia
Narcolepsy is a chronic disabling neurologic disorder mainly characterised by excessive daytime sleepiness. Type 1 narcolepsy is associated with a deficit of hypocretin in the cerebrospinal fluid responsible for the cataplexy…
- Trial name
- COGNAR (NCT05773872)
- Testing
- Questionary
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Intensive Care Unit (ICU), Sleep Disruption
Impact on Prognosis of Increased Sleep Quality Obtained by Personalized Night-time Nursing Care in Critically Ill Patients
Sleep disturbances are common among intensive care unit (ICU) patients and have been associated with difficult weaning from invasive mechanical ventilation, with an increased risk of endotracheal intubation.
- Conditions
- Intensive Care Unit (ICU), Sleep Disruption, Sleep Monitoring
- Trial name
- MEDICOSLEEP (NCT07606495)
- Testing
- Sleepscan device, Sleep-guided nursing care
- Where
- 7 sites in France
- Volunteers
- 460 people
- Sponsor
- Poitiers University Hospital
Shift Work
Effects of Operational Naps on Blood Pressure and Performance Among Night Shift Workers
Night shift work schedules disrupt sleep and have a negative impact on cardiovascular health. Most who work in public safety occupations and in healthcare work night shifts.
- Trial name
- EONN (NCT07217769)
- Testing
- No-nap, 15-min nap, 30-min nap
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Narcolepsy Type 1, Hypersomnolence
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
Mind wandering is a state in which attention turns away from the external environment or current task to focus on internal thoughts (past experiences, future events, planned actions...).
- Conditions
- Narcolepsy Type 1, Hypersomnolence, Idiopathic Hypersomnia
- Trial name
- NARCOWANDERING (NCT06457945)
- Testing
- ASRT, Questionnaires, Electrophysiological recordings
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Hospices Civils de Lyon
Chronic Insomnia, Sleep Deprivation
Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
This clinical trial aims to evaluate the safety and efficacy of PROSOMNIA Sleep Therapy (PSTx) for individuals suffering from chronic insomnia, sleep deprivation, and REM sleep disorders.
- Conditions
- Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder, REM Sleep Behavior Disorder
- Trial name
- PSHW (NCT06644573)
- Testing
- PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Nyree Penn
Narcolepsy Type 1, Narcolepsy Type 2
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]).
- Trial name
- NCT07598708
- Testing
- cleminorexton
- Where
- 26 sites in United States
- Volunteers
- 222 people
- Sponsor
- Centessa Pharmaceuticals (UK) Limited
Idiopathic Hypersomnia
Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.
This Phase II clinical trial is a monocenter, double-blind, randomized, placebo-controlled study aimed at evaluate the efficacy and safety of solriamfetol from 75 to 300 mg per day in IH patients.
- Trial name
- SOLR-IH (NCT06590662)
- Testing
- Solriamfetol
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
Narcolepsy Type 1
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
The main aim is to evaluate the safety and tolerability of TAK-861 in participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
- Trial name
- NCT05816382
- Testing
- TAK-861
- Where
- 52 sites in United States, Australia and 10 more
- Volunteers
- 500 people
- Sponsor
- Takeda